Novo Nordisk said China's National Intellectual Property Adm
文 / 小金
2026-11-10 13:40:03
来源:亚金网
Novo Nordisk said China's National Intellectual Property Administration has approved a 5-year patent term extension for the chronic kidney disease (CKD) indication of its semaglutide injection (brand Nuohetai), extending patent protection to March 2031.
